Bioventus Inc. (BVS) Misses Q2 EPS by 6c; Offers FY22 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. GOOGL
9. RTX
10. COF

Go back to Bioventus Inc. (BVS) Misses Q2 EPS by 6c; Offers FY22 Guidance

Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance

August 11, 2022 7:00 AM EDT

DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 2, 2022.

Q2 Financial Summary & Recent Highlights:

Net Sales of $140.3 million, up $30.5 million, or 27.8%, year-over-year as reported (28.6% constant currency*) and 8.1% organically* (8.8% constant currency*)Net Loss of ($8.0) million, compared to ($10.8) million in prior-year periodAdjusted EBITDA* of $22.9 million, compared to $19.9 million in prior-year periodLoss per share of Class A common stock of ($0.11), compared to... More